Search results
Factor XI Inhibition and AF
Added:
9 months ago
Article
Added:
1 year ago
Added:
9 months ago
ACC 2025 - Individual-level data collected across 126 worldwide cohorts show controlling modifiable cardiovascular risk factors can potentially benefit life-years for freedom from CVD and death from any cause.Prof Christina Magnussen (University Heart and Vascular Centre Hamburg, Hamberg, DE) joins us onsite at ACC to discuss modifiable cardiovascular risk factors collected by the Global…
View more
Added:
1 year ago
Xi Chen
Research Area(s) / Expertise:
Author
Added:
4 months ago
Presented at the European Society of Cardiology (ESC) Congress 2025, Prof Carolyn Lam (Singapore, UK), Prof Davide Capodanno (Catania, IT), Dr Sneha Shah Jain (Stanford, US) and Prof Jeffrey Weitz (Hamilton, CA) examine the prevalence and challenges of stroke prevention in atrial fibrillation (AF) and after acute coronary syndrome (ACS). The faculty review current treatment guidelines, explore…
View more
Start date:
Oct 06, 2025
Following the ESC 2025 symposium 'Revolutionising Thrombosis Treatment in ACS, SSP and AF – Bridging the Gaps With Next Generation Anticoagulation Strategies', this live Q&A webinar offers an exclusive chance to continue the conversation.Join Prof Carolyn Lam (Singapore, UK), Prof Jeffrey Weitz (Hamilton, CA) and Dr Sneha Shah Jain (Stanford, US) as they address your questions on stroke…
View more
Added:
2 years ago
AHA 23 - Dr Naima Maqsood, CardioNerds ambassador (Temple University Hospital, US) interviews Dr Christian Ruff (Brigham and Women's Hospital, US) on the late-breaking findings from the AZALEA-TIMI 71 randomized trial (Anthos Theraputics, Inc).AZALEA-TIMI 71 aimed to evaluate the bleeding profile of abelacimab as compared to rivaroxaban in patients with atrial fibrillation who are at moderate to…
View more
Added:
11 months ago
Jingda Tang
Research Area(s) / Expertise:
Author